Latest news with #RHHBY
Yahoo
3 days ago
- Business
- Yahoo
Roche extends trials of antibiotic against resistant superbug, FT reports
Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had potential to tackle a common superbug that has become resistant to other treatments, The Financial Times's Hannah Kuchler reports. If successful, it would be the first new class of antibiotic capable of killing acinetobacter or any other 'Gram-negative' bacteria to be developed for more than 50 years, the report says. Roche plans to launch a phase 3 trial for zosurabalpin at the end of the year, or early next year, Kuchler writes. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on RHHBY: Disclaimer & DisclosureReport an Issue Tandem Diabetes, Roche enter patent settlement agreement Roche announces EMA's CHMP has adopted positive opinion for Itovebi Genentech announces two-year follow-up data from STARGLO study Roche's Genentech announces FDA approval of Susvimo for diabetic retinopathy Trump Trade: White House announces 'Golden Dome' missile-defense shield
Yahoo
23-05-2025
- Business
- Yahoo
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
This week, Novo Nordisk NVO announced the surprise resignation of its chief executive officer (CEO), Lars Fruergaard Jørgensen. Sanofi SNY announced the proposed acquisition of Vigil Neuroscience, a clinical-stage biotech focused on developing treatments for neurodegenerative diseases. Pfizer PFE announced a licensing deal with Chinese biotech 3SBio. The FDA granted approval to Roche's RHHBY eye drug, Susvimo, for its third indication in the United States. Merck MRK and its Japanese partner Daiichi Sankyo began a pivotal study on ifinatamab deruxtecan in esophageal cancer. Here's a recap of the week's most important stories. Novo Nordisk announced that its CEO, Lars Fruergaard Jørgensen, will step down from his position. The decision can be attributed to increasing competitive pressure and recent market challenges that have led to a decline in the company's stock price since mid-2024. Also, the Novo Nordisk Foundation board asked for a CEO succession and an increased presence on the NVO board. Novo Nordisk Foundation controls the majority of votes at the Novo Nordisk annual general meeting. Accordingly, Lars Rebien Sørensen, chair of the Novo Nordisk Foundation, will join NVO's board as an observer for some time. Jørgensen's decision comes after a mutual agreement with the board, although he will remain in his role temporarily to ensure a smooth transition. Jørgensen has been CEO since 2017 and played a pivotal role in the company's expansion, particularly in the obesity treatment market, which has been a significant growth driver for Novo Nordisk in recent years. Novo Nordisk said a search for Lars Fruergaard Jørgensen's successor has begun. Sanofi announced an agreement to acquire Vigil Neuroscience, which is making innovative TREM2-based therapeutics for neurodegenerative diseases, for a total equity value of around $470 million ($8 per share in cash). The acquisition will add Vigil's investigational oral small-molecule TREM2 agonist, VG-3927, which will be developed in a phase II study for treating Alzheimer's disease. However, Sanofi is not acquiring VGL101, Vigil's second molecule program, which is being developed for another neurodegenerative disease. Pfizer announced an exclusive deal to acquire global (ex-China) rights to SSGJ-707, a bispecific PD-1/VEGF antibody developed by Chinese biotech 3SBio, for an upfront payment of $1.25 billion. The deal includes up to $4.8 billion in milestone payments, tiered double-digit royalties, and a $100 million equity investment in 3SBio. SSGJ-707 is being developed for cancers such as non-small cell lung cancer and metastatic colorectal cancer, with a phase III trial expected this year. Unlike existing PD-1 therapies, SSGJ-707 targets both PD-1 and VEGF, potentially offering a stronger anti-tumor response. The deal is set to be closed in the third quarter. The FDA approved Roche's eye drug, Susvimo, for treating diabetic retinopathy (DR). Susvimo is already approved for treating neovascular or 'wet' age-related macular degeneration and diabetic macular edema. The approval was based on one-year data from the phase III Pavilion study. Susvimo provides continuous delivery of a customized formulation of ranibizumab via the Port Delivery Platform (a refillable eye implant), offering an alternative treatment option to regular VEGF eye injections for patients at risk of vision loss from progression of diabetic retinopathy. Merck and partner Daiichi Sankyo announced the dosing of the first patient in the pivotal IDeate-Esophageal01 phase III study evaluating the efficacy and safety of ifinatamab deruxtecan (I-DXd) in certain patients with pretreated advanced or metastatic esophageal squamous cell carcinoma versus the physician's choice of chemotherapy. The study's primary endpoint is overall survival. Ifinatamab deruxtecan is also being evaluated in a phase III study in relapsed small cell lung cancer (SCLC). Ifinatamab deruxtecan is a part of Merck's collaboration with Daiichi Sankyo to co-develop and co-commercialize the latter's three DXd antibody drug conjugates or ADCs worldwide, except Japan. The other two ADCs are patritumab deruxtecan/MK-1022 and raludotatug deruxtecan/MK-5909. In August last year, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its acquisition of Harpoon Therapeutics. Pfizer has a Zacks Rank #2 (Buy), while Novo Nordisk, Pfizer, Sanofi and Merck carry a Zacks Rank of 3 (Hold) each. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The NYSE ARCA Pharmaceutical Index has declined 3.8% in the past five trading sessions. Large Cap Pharmaceuticals Industry 5YR % Return Here's how the eight major stocks performed in the previous five trading sessions. Image Source: Zacks Investment Research In the last five trading sessions, Merck rose the most (4.1%) while Lilly declined the most (2.3%). In the past six months, Novartis rose the most (11.2%), while Novo Nordisk declined the most (34.0%). (See the last pharma stock roundup here: BAYRY Q1 Earnings, NVO & GSK's New Deals) Watch this space for regular pipeline and regulatory updates next week. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
13-05-2025
- Business
- Globe and Mail
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US
Less than a month after announcing a $50 billion investment in its U.S. operations over the next five years, Swiss pharma giant Roche RHHBY has started rolling out the details of its plans. RHHBY unveiled plans to invest over $700 million in a new 700,000-square-foot, state-of-the-art drug manufacturing facility in Holly Springs, NC. Through this new plant, the company intends to support its pipeline of next-generation obesity drugs for Genentech, a member of the Roche group. Roche expects the project to generate over 1,500 construction jobs and more than 400 high-wage, permanent positions once it is operational. In a press release, Roche mentioned that it could further expand the initial investment in this plant based on "business needs and the US policy environment." RHHBY also announced plans to expand its diagnostic site in Indianapolis. In this regard, it plans to spend up to $550 million by 2030 to establish the site as "a major hub for the manufacturing" of the company's continuous glucose monitoring (CGM) systems. Per Roche, this expansion will "create hundreds of jobs while also enhancing U.S. production capabilities." RHHBY Stock Performance Year to date, shares of Roche have risen 13% against the industry 's 6% decline. Here's Why RHHBY is Expanding Its Manufacturing Presence in US These investments reflect Roche's broader commitment to strengthening its U.S. infrastructure amid Trump's proposed tariffs on pharmaceutical imports. The company's U.S. footprint currently includes 13 manufacturing and 15 R&D sites across its Pharmaceutical and Diagnostics Divisions in eight states. Trump has announced plans to impose tariffs on pharmaceutical imports (which have been largely exempt until now) to incentivize drugmakers to relocate their operations to the United States. He stated that the United States offers a very big market, and the new tariffs will propel pharmaceutical companies to rush back to the country. Per reports, the United States imports large amounts of finished drugs and active pharmaceutical ingredients (APIs) from other countries. Big Pharma Commits Over $100B to US Expansion Similar to Roche, several other large pharmaceutical companies have earmarked investments to expand their manufacturing presence in the country. Eli Lilly LLY was one of the first pharma companies to unveil investment plans. In February, LLY announced plans to invest $27 billion in building four new manufacturing sites in the United States in 2025, bringing its total domestic manufacturing expansion commitments since 2020 to more than $50 billion. Previously, from 2020 to 2024, Lilly committed more than $23 billion to domestic capital expansion. The increased manufacturing investment can boost production capacity for its medicines, particularly its popular GLP-1 products, Mounjaro and Zepbound. J&J JNJ has committed more than $55 billion in the country over the next four years to boost manufacturing, R&D and technology. This represents a 25% increase in investment compared to the previous four years. JNJ believes that the U.S. economic impact of the increased U.S. investment will exceed $100 billion a year. J&J's investments begin with the groundbreaking of a high-tech 500,000-square-foot, state-of-the-art biologics manufacturing facility in North Carolina. Last month, Novartis NVS announced a planned $23 billion investment over five years in U.S.-based infrastructure. Backed by this investment, NVS intends to manufacture all key drugs for its U.S. patients in the country. Over the next five years, Novartis will establish a biomedical research innovation hub in San Diego, CA, its second global R&D hub in the country, expected to open during 2028-2029. Novartis will build four new manufacturing facilities across three states. RHHBY's Zacks Rank Roche currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Yahoo
09-04-2025
- Business
- Yahoo
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple sclerosis (RMS) compared with the currently approved Ocrevus IV 600 mg dose. Patients received treatment with Ocrevus high dose or IV 600 mg every 24 weeks for a minimum of 120 weeks. The trial did not meet its primary endpoint in showing additional benefit in slowing disability progression, as measured by a composite disability over a period of at least 120 weeks of treatment. Also Read: The rates of disability progression were low and consistent with rates observed in the previous pivotal studies of Ocrevus IV 600 mg. In addition, in several predefined analyses on disease activity, Ocrevus IV 600 mg showed clinically meaningful results with the lowest annualized relapse rate (ARR) observed during the double-blind period of a Phase III study in RMS. The MUSETTE data further support the efficacy and safety profile of the currently approved OCREVUS IV 600 mg dose for RMS. Ocrevus IV and Ocrevus subcutaneous (SC; marketed as OCREVUS ZUNOVO [ocrelizumab hyaluronidase-ocsq] in the U.S.) are approved for both RMS (including relapsing-remitting multiple sclerosis and active, or relapsing secondary progressive multiple sclerosis, as well as clinically isolated syndrome in the U.S.) and primary progressive multiple sclerosis. Both Ocrevus IV and subcutaneous are administered every six months. The initial IV dose is given as two 300 mg infusions two weeks apart, with subsequent doses given as single 600 mg infusions. Ocrevus subcutaneous is given as a single 920 mg subcutaneous injection every six months. Price Action: RHHBY stock is down 3.89% at $39.48 at the last check Wednesday. Read Next:Photo by OleksSH via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Why Is Pharma Giant Roche Stock Trading Lower On Wednesday? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
07-03-2025
- Business
- Yahoo
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More
This week, Bayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm Gubra for an amylin-targeting obesity treatment, which marked the company's entry into the obesity space. Novo Nordisk NVO announced that it is cutting the price of its popular obesity injection, Wegovy, for the uninsured following a similar move by rival Eli Lilly. J&J JNJ discontinued a phase III study on a candidate being evaluated as an adjunctive treatment for major depressive disorder (aMDD). The FDA accepted Roche's RHHBY application seeking expanded use of its lymphoma drug, Gazyva/Gazyvaro, for the treatment of lupus nephritis. Here's a recap of the week's most important stories. Novo Nordisk is launching a new direct-to-patient online pharmacy called NovoCare, which will offer Wegovy at a discounted price of $499 per month, less than half of its listed price. This offer is for patients who do not have insurance coverage and pay by cash as well as those with insurance but have no coverage for obesity medicines. The website provides an option for these patients to have their injections delivered to their homes. Novo Nordisk's announcement follows a similar move by rival Eli Lilly. Last week, Lilly also announced that it is reducing the prices of its 7.5 mg and 10 mg single-dose vials of obesity treatment Zepbound to $499 per month for customers paying through a new self-pay program called LillyDirect Self-Pay Pharmacy Solutions. Bayer's fourth-quarter core earnings of €1.05 per share declined 43.2% year over year. Sales of €11.7 billion rose 0.1% on a currency and portfolio-adjusted basis. Sales in the Crop Science segment decreased 2.3%. Pharmaceuticals segment sales increased 2.4%, while Consumer Health sales declined 0.9% on a currency and portfolio-adjusted basis. In the Pharmaceuticals segment, sales of new products, cancer drug Nubeqa and kidney drug, Kerendia, remained strong, offsetting the loss of exclusivity impact on sales of oral anticoagulant Xarelto. The pace of growth in the Consumer Health business has slowed down. The Crop Science business was adversely impacted by lower prices in the crop protection business due to competitive pricing pressure. Bayer issued a financial guidance for 2025. The company expects 2025 to be a 'pivotal year' and the most difficult in terms of financial performance. Sales are expected to be in the range of €45-€47 billion in 2025. Core EPS is projected to be in the band of €4.50-€5.00. Bayer expects its performance to improve from 2026. AbbVie in-licensed rights to develop a phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity from Danish biotech, Gubra. AbbVie will lead the development of the candidate. For the deal, which marks AbbVie's entry into the obesity space, it will make an upfront payment of $350 million to Gubra. It will also pay milestone payments of up to $1.875 billion to Gubra. The FDA accepted a supplemental biologics license application (sBLA) seeking approval for Roche's Gazyva/Gazyvaro for the treatment of lupus nephritis. The sBLA was based on based on data from the phase III REGENCY study. The FDA's decision on the sBLA is expected by October 2024. A similar application is also under review in the EU. Gazyva/Gazyvaro is presently approved for treating various types of lymphoma. J&J announced the discontinuation of the phase III VENTURA program on pipeline candidate, aticaprant, for aMDD. The decision to end the program was based on the lack of sufficient efficacy observed in the target patient population. Data from the study showed that aticaprant was safe and well tolerated. J&J, Novo Nordisk, Roche, AbbVie and Bayer carry a Zacks Rank #3 (Hold) each. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The NYSE ARCA Pharmaceutical Index has risen 2% in the past five trading sessions. Large Cap Pharmaceuticals Industry 5YR % Return Here's how the eight major stocks performed in the previous five trading sessions. Image Source: Zacks Investment Research In the last five trading sessions, Merck rose the most (3.8%), while Novo Nordisk declined the most (1.3%). In the past six months, AbbVie rose the most (7.3%), while Novo Nordisk declined the most (33.3%). (See the last pharma stock roundup here: LLY Ups U.S. Manufacturing Investments & More) Watch this space for regular pipeline and regulatory updates next week. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
